CAMBRIDGE, England, July 14, 2011 /PRNewswire/ --
Executives from O2h (Cambridge, UK) and Heptares Therapeutics (Welwyn Garden City, UK) signed an agreement to substantially increase the number of FTE chemists provided by O2h to support discovery programmes at Heptares.
Dr Miles Congreve, Head of Chemistry at Heptares said, "O2h has been a valuable partner for Heptares and we are happy to further extend our synthetic chemistry team to include a full lab unit at O2h."
O2h's 12 FTE lab units are modular, fully-customizable, well-equipped and IT-secure spaces which offer the optimum environment for highly productive, dedicated chemistry teams.
"Heptares has built some great partnerships with large biotechnology and pharma companies who recognize the strength of the Company's GPCR expertise and proprietary StaR® technology's. This is a new milestone in our on-going relationship with Heptares and we are excited to support them on their journey," said Sunil Shah, CEO, O2h.
About Heptares Therapeutics
Heptares is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs). The Company is currently leveraging its GPCR expertise and proprietary StaR® technology to build a pipeline of best-in-class and first-in-class GPCR-targeted medicines for the treatment of CNS, metabolic and other diseases.
GPCRs represent the single most important family of drug targets
in the human body, yet, due to their inherent instability when
removed from cell membranes, little or no structural information
about these valuable targets has been available to drive
structure-based drug discovery programmes. Heptares' StaR®
(Stabilised Receptor) technology enables the first-ever
thermo-stabilisation of GPCRs. This breakthrough allows Heptares
scientists to resolve GPCR structures and deploy structure-based
drug discovery techniques to identify potent a
|SOURCE Oxygen Healthcare Ltd (O2h)|
Copyright©2010 PR Newswire.
All rights reserved